By using shRNA and CRISPR-Cas9, stomach cancer (Cdh1-/-; Tp53-/-) [31], colon cancer (APC, TP53, KRAS and Smad4 mutations) [28, 29, 32], pancreatic cancer (KRAS and/or TP53 mutations) [17, 33] and lung adenocarcinoma organoids (HER2 overexpression) could be efficiently generated [30]. Here, KRAS is linked to malignant colon neoplasm.